Literature DB >> 25883810

Comment on "A Unique Case of Cardiac Arrest following K2 Abuse".

Joachim Alexandre1, Danièle Debruyne2, Antoine Coquerel3, Reynald Le Boisselier2.   

Abstract

Entities:  

Year:  2015        PMID: 25883810      PMCID: PMC4391492          DOI: 10.1155/2015/739149

Source DB:  PubMed          Journal:  Case Rep Cardiol        ISSN: 2090-6404


× No keyword cloud information.
We appreciated reading the paper by Ibrahim et al. [1] describing the impact of K2 abuse on sudden cardiac death (SCD). This paper, although it provides interesting information about synthetic cannabinoid (SC), it also presents several limitations. Notably, the authors formally connected the K2 abuse and the SCD. In contrast to Ibrahim et al., we think that the SCD is mainly related to the cardiac history of the patient. Substantial evidence supports our point of view. First, the patient had a past cardiological history with a previous myocardial infarction (MI) and four-vessel coronary artery bypass graft 10 years ago. Authors did not specify where the MI was located but we can suppose, from the electrocardiogram (ECG) in sinus rhythm, that it was an inferior MI (Q wave in inferior derivations). Moreover, authors did not specify the exact coronary lesions in native vessels. It would be interesting to know if one vessel (right coronary artery) was occluded. All these elements are important because it is well established that most of SCD cases in coronary artery disease patients occur on previous myocardial scar (which is the consequence of a coronary artery occlusion and results in the presence of Q wave in a coronary artery territory) and typically 10 years after MI [2-4]. Another element that supports our hypothesis is that authors declare that “the cardiac arrest was not associated with an acute coronary occlusion” [1] which is largely in favor of our theory. So it seems more reasonable to think that cardiac arrest is the consequence of a malignant reentrant ventricular arrhythmia than K2 abuse [2, 3]. It seems also difficult to conclude a myocardial necrosis based on moderate troponin T elevation (0.632). It would be helpful to specify the laboratory standards for the troponin T. The moderate elevation seems more likely due to the resuscitation (drugs, defibrillation, cardiac massage…) than a real myocardial necrosis which usually leads to major troponin T elevations [5]. Second, we have serious concerns regarding some cardiological interpretation of this observation. In fact, authors interpreted the ECG on admission [1] as a sinus tachycardia. It is wrong. This ECG shows a typical atrial flutter with a 2/1 ventricular conduction. We can recognize the atrial flutter with a regular and typical atrial activation near 240/min, uniform and continuous in all leads, with the typical “sawtooth” pattern in the inferior leads (manifested by a notching of the end of the QRS complex, clearly visible in V1 derivation and disappears during sinus rhythm in the second ECG presented by Ibrahim et al.). There is a classically 2 : 1 ventricular response [6]. The very long PR interval observed during tachycardia and absent in sinus rhythm also indicated that the rhythm cannot be sinusal in the first ECG. Atrial flutter following a cardiac arrest is classical when using drugs such as epinephrine or adrenaline and disappears most frequently in few hours or a day [7]. Regarding ECGs, we agree that cannabinoids have an impact on several ion channels but it seems difficult to directly link these properties to ECG changes, especially since the patient already has changes on his baseline ECG due to his coronary artery disease (and possibly antiarrhythmic drugs). Third, evidence supports that cannabis is now a well-known trigger for MI [8, 9]. However, the challenge remains to link clearly the cardiac event to cannabinoids consumption and case reports are most often published without a clear etiology, with conclusions which are therefore most speculative. Conversely, the SC impact on serious cardiac events remains to date unknown, even if there are serious concerns [10-15]. The increasing use of SC as drug of abuse and their consequences in terms of public health have, therefore, to be closely monitored, especially considering pharmacological properties as the higher affinity for cannabinoid receptors than natural cannabinoid delta-9 THC resulting in higher pharmacological activity, early demonstrated with first SC [16, 17]. This present case report by Ibrahim et al. is therefore consistent with previously published reports but, to our knowledge, cannot reliably connect SC and SCD. In conclusion, there are several evidences [10-15] to think that cannabis and SC can lead to serious cardiac disorders but we think that this case report is speculative rather than affirmative (because of the study limitations described above) and therefore, conclusions should be more modulated.
  17 in total

1.  Myocardial infarction following cannabis induced coronary vasospasm.

Authors:  Mudalige Don Vajira Malin Gunawardena; Senaka Rajapakse; Jagath Herath; Naomali Amarasena
Journal:  BMJ Case Rep       Date:  2014-11-12

2.  Myocardial infarction associated with use of the synthetic cannabinoid K2.

Authors:  Arshid Mir; Adebisi Obafemi; Amy Young; Colin Kane
Journal:  Pediatrics       Date:  2011-11-07       Impact factor: 7.124

3.  Sudden cardiac death complicating acute myocardial infarction following synthetic cannabinoid use.

Authors:  R Tse; S Kodur; B Squires; N Collins
Journal:  Intern Med J       Date:  2014-09       Impact factor: 2.048

4.  Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists.

Authors:  John W Huffman; Gulay Zengin; Ming-Jung Wu; Jianzhong Lu; George Hynd; Kristen Bushell; Alicia L S Thompson; Simon Bushell; Cindy Tartal; Dow P Hurst; Patricia H Reggio; Dana E Selley; Michael P Cassidy; Jenny L Wiley; Billy R Martin
Journal:  Bioorg Med Chem       Date:  2005-01-03       Impact factor: 3.641

5.  Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol.

Authors:  A Weissman; G M Milne; L S Melvin
Journal:  J Pharmacol Exp Ther       Date:  1982-11       Impact factor: 4.030

Review 6.  Cannabis-associated myocardial infarction in a young man with normal coronary arteries.

Authors:  Christopher J Hodcroft; Melissa C Rossiter; Ashesh N Buch
Journal:  J Emerg Med       Date:  2014-07-02       Impact factor: 1.484

7.  Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators.

Authors:  M A Mittleman; M Maclure; J B Sherwood; R P Mulry; G H Tofler; S C Jacobs; R Friedman; H Benson; J E Muller
Journal:  Circulation       Date:  1995-10-01       Impact factor: 29.690

8.  Both beta 1- and beta 2-adrenoceptors mediate catecholamine-evoked arrhythmias in isolated human right atrium.

Authors:  A J Kaumann; L Sanders
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-11       Impact factor: 3.000

9.  Scar extent as a predictive factor of ventricular tachycardia cycle length after myocardial infarction: implications for implantable cardioverter-defibrillator programming optimization.

Authors:  Joachim Alexandre; Eric Saloux; Alain Lebon; Audrey Emmanuelle Dugué; Adrien Lemaitre; Vincent Roule; Fabien Labombarda; Laure Champ-Rigot; Sophie Gomes; Arnaud Pellissier; Patrice Scanu; Paul Milliez
Journal:  Europace       Date:  2013-11-01       Impact factor: 5.214

10.  Cannabis use: signal of increasing risk of serious cardiovascular disorders.

Authors:  Emilie Jouanjus; Maryse Lapeyre-Mestre; Joelle Micallef
Journal:  J Am Heart Assoc       Date:  2014-04-23       Impact factor: 5.501

View more
  1 in total

Review 1.  Emerging drugs of abuse: current perspectives on synthetic cannabinoids.

Authors:  Danièle Debruyne; Reynald Le Boisselier
Journal:  Subst Abuse Rehabil       Date:  2015-10-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.